Zurich Cantonal Bank
NERV icon

Zurich Cantonal Bank’s Minerva Neurosciences NERV Stock Holding History

Zurich Cantonal Bank’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-558
Closed -$35K – 2609
2019
Q3 		$35K Buy
+558
New +$31.6K ﹤0.01% 2246

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Zurich Cantonal Bank's NERV Position: Q4 2019 in Review

Zurich Cantonal Bank sold out of Minerva Neurosciences (NERV) in Q4 2019, closing a stake of 558 shares — an estimated $35K sold.

Zurich Cantonal Bank first reported a position in NERV in Q3 2019 and held it in 1 quarter. The position peaked at $35K in Q3 2019. 92 funds tracked by Wall St. Rank hold NERV as of Q4 2019.

  • Zurich Cantonal Bank reported no remaining Minerva Neurosciences position as of Q4 2019 after selling out during the quarter.
  • Zurich Cantonal Bank sold 558 Minerva Neurosciences shares in Q4 2019, an estimated $35K.
  • Zurich Cantonal Bank first reported a position in Minerva Neurosciences in Q3 2019 and held it in 1 quarter.
  • Zurich Cantonal Bank's Minerva Neurosciences position peaked at $35K in Q3 2019.
  • 92 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2019.

Based on Zurich Cantonal Bank's 13F filing for Q4 2019, filed 21 Jan 2020.